CNBX — CNBX Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $0.01m
- $1.37m
- $0.13m
Annual income statement for CNBX Pharmaceuticals, fiscal year end - August 31st, USD millions except per share, conversion factor applied.
2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.007 | 0 | 0 | 0.41 | 0.13 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 3.05 | 2.6 | 2.95 | 1.34 | 0.713 |
| Operating Profit | -3.04 | -2.6 | -2.95 | -0.931 | -0.583 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.47 | -3.19 | -3.72 | -3.71 | -0.695 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.47 | -3.19 | -3.72 | -3.71 | -0.695 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.47 | -3.19 | -3.72 | -3.71 | -0.695 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.47 | -3.19 | -3.72 | -3.71 | -0.695 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6.66 | -2.77 | -3.06 | -0.42 | -0.023 |